LPC
Lion Point Capital Portfolio holdings
AUM
$14.7M
This Quarter Return
-8.28%
1 Year Return
+16.78%
3 Year Return
+52.25%
5 Year Return
+189.95%
10 Year Return
–
AUM
$15.7M
AUM Growth
+$15.7M
(-18%)
Cap. Flow
-$221K
Cap. Flow
% of AUM
-1.41%
Top 10 Holdings %
Top 10 Hldgs %
72.96%
Holding
21
New
2
Increased
2
Reduced
3
Closed
–
Top Buys
| 1 |
Jasper Therapeutics
JSPR
|
$492K |
| 2 |
AVDL
Avadel Pharmaceuticals
AVDL
|
$272K |
| 3 |
Mersana Therapeutics
MRSN
|
$222K |
| 4 |
Humacyte
HUMA
|
$142K |
Top Sells
| 1 |
BridgeBio Pharma
BBIO
|
$494K |
| 2 |
Insmed
INSM
|
$473K |
| 3 |
Milestone Pharmaceuticals
MIST
|
$382K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Insmed
INSM
$28.8B
| $2.33M | 14.84% | 30,500 -6,200 | -17% | -$473K |
|
2
Ardelyx
ARDX
$1.53B
| $1.65M | 10.51% | 335,400 | – | – |
|
3
Mineralys Therapeutics
MLYS
$1.03B
| $1.25M | 8% | 79,000 | – | – |
|
4
Fennec Pharmaceuticals
FENC
$247M
| $1.19M | 7.6% | 195,700 | – | – |
|
5
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $1.02M | 6.5% | 45,900 | – | – |
|
|
6
BridgeBio Pharma
BBIO
$9.89B
| $899K | 5.73% | 26,000 -14,300 | -35% | -$494K |
|
7
Benitec Biopharma
BNTC
$348M
| $807K | 5.15% | 62,000 | – | – |
|
8
Geron
GERN
$893M
| $795K | 5.07% | 500,000 | – | – |
|
|
AVDL
9
Avadel Pharmaceuticals
AVDL
$1.43B
| $773K | 4.93% | 98,700 +34,700 | +54% | +$272K |
|
10
Arcutis Biotherapeutics
ARQT
$1.86B
| $724K | 4.62% | 46,300 | – | – |
|
11
Syndax Pharmaceuticals
SNDX
$1.41B
| $676K | 4.31% | 55,000 | – | – |
|
|
12
Jasper Therapeutics
JSPR
$45.5M
| $630K | 4.02% | 146,500 +114,500 | +358% | +$492K |
|
13
Biohaven
BHVN
$1.63B
| $546K | 3.48% | 22,700 | – | – |
|
14
Disc Medicine
IRON
$2.07B
| $526K | 3.36% | 10,600 | – | – |
|
|
15
Milestone Pharmaceuticals
MIST
$156M
| $439K | 2.8% | 548,806 -477,000 | -47% | -$382K |
|
16
Regenxbio
RGNX
$451M
| $413K | 2.63% | 57,750 | – | – |
|
|
BLUE
17
DELISTED
bluebird bio
BLUE
| $385K | 2.46% | 78,912 | – | – |
|
18
Seres Therapeutics
MCRB
$166M
| $239K | 1.52% | 340,761 | – | – |
|
|
19
Mersana Therapeutics
MRSN
$36.5M
| $222K | 1.41% | +644,000 | New | +$222K |
|
|
20
Humacyte
HUMA
$245M
| $142K | 0.91% | +83,500 | New | +$142K |
|
|
SPRB
21
DELISTED
Spruce Biosciences, Inc. Common Stock
SPRB
| $21.8K | 0.14% | 75,000 | – | – |
|